Cargando…

Circulating CD81-expressing extracellular vesicles as biomarkers of response for immune-checkpoint inhibitors in advanced NSCLC

PD-L1 in tumor cells is the only used biomarker for anti PD1/PD-L1 immune-checkpoints inhibitors (ICI) in Non Small Cell Lung Cancer (NSCLC) patients. However, this parameter is inaccurate to predict response, especially in patients with low tumor PD-L1. Here, we evaluated circulating EVs as possibl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Signorelli, Diego, Ghidotti, Patrizia, Proto, Claudia, Brambilla, Marta, De Toma, Alessandro, Ferrara, Roberto, Galli, Giulia, Ganzinelli, Monica, Lo Russo, Giuseppe, Prelaj, Arsela, Occhipinti, Mario, Viscardi, Giuseppe, Capizzuto, Valentina, Pontis, Francesca, Petraroia, Ilaria, Ferretti, Anna Maria, Colombo, Mario Paolo, Torri, Valter, Sozzi, Gabriella, Garassino, Marina Chiara, Jachetti, Elena, Fortunato, Orazio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9530186/ https://www.ncbi.nlm.nih.gov/pubmed/36203609 http://dx.doi.org/10.3389/fimmu.2022.987639

Ejemplares similares

Integrating clinical and biological prognostic biomarkers in patients with advanced NSCLC treated with immunotherapy: the DEMo score system
por: Prelaj, Arsela, et al.
Publicado: (2020)

Novel patterns of progression upon immunotherapy in other thoracic malignancies and uncommon populations
por: Ferrara, Roberto, et al.
Publicado: (2021)

EPSILoN: A Prognostic Score for Immunotherapy in Advanced Non-Small-Cell Lung Cancer: A Validation Cohort
por: Prelaj, Arsela, et al.
Publicado: (2019)

Case Report: Exceptional Response to Poziotinib in Patient with Metastatic Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutation
por: Prelaj, Arsela, et al.
Publicado: (2022)

Extracellular vesicles from subjects with COPD modulate cancer initiating cells phenotype through HIF-1α shuttling
por: Petraroia, Ilaria, et al.
Publicado: (2023)

Machine Learning Using Real-World and Translational Data to Improve Treatment Selection for NSCLC Patients Treated with Immunotherapy
por: Prelaj, Arsela, et al.
Publicado: (2022)

Evaluation of Drug—Drug Interactions in EGFR-Mutated Non-Small-Cell Lung Cancer Patients during Treatment with Tyrosine-Kinase Inhibitors
por: Occhipinti, Mario, et al.
Publicado: (2021)

SMO mutations confer poor prognosis in malignant pleural mesothelioma
por: Signorelli, Diego, et al.
Publicado: (2020)

MiR-223 Exclusively Impairs In Vitro Tumor Growth through IGF1R Modulation in Rhabdomyosarcoma of Adolescents and Young Adults
por: Casanova, Michela, et al.
Publicado: (2022)

PEOPLE (NTC03447678), a phase II trial to test pembrolizumab as first-line treatment in patients with advanced NSCLC with PD-L1 <50%: a multiomics analysis
por: Lo Russo, Giuseppe, et al.
Publicado: (2023)

Is There an Interplay between Immune Checkpoint Inhibitors, Thromboprophylactic Treatments and Thromboembolic Events? Mechanisms and Impact in Non-Small Cell Lung Cancer Patients
por: Nichetti, Federico, et al.
Publicado: (2019)

Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors
por: Fucà, Giovanni, et al.
Publicado: (2019)

Real-world data to build explainable trustworthy artificial intelligence models for prediction of immunotherapy efficacy in NSCLC patients
por: Prelaj, Arsela, et al.
Publicado: (2023)

Is hyperprogressive disease a specific phenomenom of immunotherapy?
por: Brambilla, Marta, et al.
Publicado: (2020)

PEOPLE (NCT03447678), a first-line phase II pembrolizumab trial, in negative and low PD-L1 advanced NSCLC: clinical outcomes and association with circulating immune biomarkers
por: Lo Russo, G., et al.
Publicado: (2022)

LKB1 mutations are not associated with the efficacy of first-line and second-line chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC): a post hoc analysis of the TAILOR trial
por: Vernieri, Claudio, et al.
Publicado: (2020)

Beyond First-Line Immunotherapy: Potential Therapeutic Strategies Based on Different Pattern Progressions: Oligo and Systemic Progression
por: Prelaj, Arsela, et al.
Publicado: (2021)

Beyond LKB1 Mutations in Non-Small Cell Lung Cancer: Defining LKB1less Phenotype to Optimize Patient Selection and Treatment
por: Borzi, Cristina, et al.
Publicado: (2020)

Circulating extracellular vesicles from individuals at high-risk of lung cancer induce pro-tumorigenic conversion of stromal cells through transfer of miR-126 and miR-320
por: Pontis, Francesca, et al.
Publicado: (2021)

Concomitant EML4-ALK rearrangement and EGFR mutation in non-small cell lung cancer patients: a literature review of 100 cases
por: Lo Russo, Giuseppe, et al.
Publicado: (2017)

Cotargeting of miR‐126‐3p and miR‐221‐3p inhibits PIK3R2 and PTEN, reducing lung cancer growth and metastasis by blocking AKT and CXCR4 signalling
por: Di Paolo, Daniela, et al.
Publicado: (2021)

Treatment patterns among patients with malignant pleural mesothelioma: An Italian, population‐based nationwide study
por: Trama, Annalisa, et al.
Publicado: (2020)

The metastatic niche formation: focus on extracellular vesicle-mediated dialogue between lung cancer cells and the microenvironment
por: Pontis, Francesca, et al.
Publicado: (2023)

Radium-223 in patients with metastatic castration-resistant prostate cancer: Efficacy and safety in clinical practice
por: Prelaj, Arsela, et al.
Publicado: (2019)

TERAVOLT: Thoracic Cancers International COVID-19 Collaboration
por: Whisenant, Jennifer G., et al.
Publicado: (2020)

Non-conventional fotemustine schedule as second-line treatment in recurrent malignant gliomas: Survival across disease and treatment subgroup analysis and review of the literature
por: Prelaj, Arsela, et al.
Publicado: (2019)

Neoadjuvant Chemotherapy in Neuroendocrine Bladder Cancer: A Case Report
por: Prelaj, Arsela, et al.
Publicado: (2016)

Randomised Phase II Trial (NCT00637975) Evaluating Activity and Toxicity of Two Different Escalating Strategies for Pregabalin and Oxycodone Combination Therapy for Neuropathic Pain in Cancer Patients
por: Garassino, Marina Chiara, et al.
Publicado: (2013)

Circulating biomarkers in malignant pleural mesothelioma
por: Viscardi, Giuseppe, et al.
Publicado: (2020)

Multimodal treatment for local recurrent malignant gliomas: Resurgery and/or reirradiation followed by chemotherapy
por: Prelaj, Arsela, et al.
Publicado: (2019)

Exo-miRNAs as a New Tool for Liquid Biopsy in Lung Cancer
por: Fortunato, Orazio, et al.
Publicado: (2019)

Successful treatment of triple EGFR mutation T785A/L861Q/H297_E298 with afatinib
por: Longo, Vito, et al.
Publicado: (2021)

Neutrophil-to-lymphocyte ratio in combination with PD-L1 or lactate dehydrogenase as biomarkers for high PD-L1 non-small cell lung cancer treated with first-line pembrolizumab
por: Banna, Giuseppe Luigi, et al.
Publicado: (2020)

Sombra 81
por: Nahum, Lucien
Publicado: (1980)

Workshop 81
por: Heagarty, Denise, et al.
Publicado: (1981)

Therapeutic Use of MicroRNAs in Lung Cancer
por: Fortunato, Orazio, et al.
Publicado: (2014)

MicroRNA Profile of Lung Tumor Tissues Is Associated with a High Risk Plasma miRNA Signature
por: Fortunato, Orazio, et al.
Publicado: (2016)

Evaluation of the efficacy of cisplatin–etoposide and the role of thoracic radiotherapy and prophylactic cranial irradiation in LCNEC
por: Prelaj, Arsela, et al.
Publicado: (2017)

The Role and the Effect of Magnesium in Mental Disorders: A Systematic Review
por: Botturi, Andrea, et al.
Publicado: (2020)

Myeloid cell heterogeneity in lung cancer: implication for immunotherapy
por: Sangaletti, Sabina, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_cn4d6eb0nm9i28gtdebk8o8deq